viral vector vaccine

6 marketed 21 in Phase 3 2 in Phase 2 1 in Phase 1

This page covers all viral vector vaccine drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting SARS-CoV-2 spike protein, Hepatitis C virus antigens, Ebola virus glycoprotein (GP).

Targets

SARS-CoV-2 spike protein · Hepatitis C virus antigens · Ebola virus glycoprotein (GP) · Filovirus glycoproteins (Ebola virus GP, Marburg virus GP) · Ebola virus glycoprotein (ZEBOV) · SARS-CoV-2 Omicron variant spike protein · Ebola virus glycoprotein (EBOV GP) · HIV-1 gp120 envelope glycoprotein · RSV prefusion F protein · Mycobacterium tuberculosis antigens (Ag85A, TB10.4)

Marketed (6)

Phase 3 pipeline (21)

Phase 2 pipeline (2)

Phase 1 pipeline (1)